Case Report of International Journal of Case Reports
Efficacy of an oral appliance in an adult Marfan syndrome patient with obstructive sleep apnea
Akifumi Enomoto*, Yuko Kinoshita, Atsushi-Doksa Lee, Miho Sukedai, Takeshi Shimoide
Department of Oral and Maxillofacial Surgery, Kindai University School of Medicine, 377-2, Ohno-higashi, Osaka-Sayama, 589-8511, Japan.
Marfan’s syndrome (MFS) is an autosomal dominant disorder that affects the body’s connective tissue, characterized by changes in three major connective tissue systems: the musculoskeletal, ocular, and cardiovascular systems. Individuals with MFS can develop severe cardiovascular complications., and the life expectancy of patients with MFS is markedly reduced as the effects of the disease on the aorta often lead to progressive dilatation, with subsequent dissection and rupture. Obstructive sleep apnea (OSA) is highly prevalent in patients with cardiovascular diseases. There is a high prevalence of OSA in patients with MFS due to craniofacial dysmorphism and increased upper airway collapsibility. A high prevalence of OSA has been reported in patients with MFS. To date, however, there are only a few case reports regarding the treatment of OSA in MFS patients. We present a treatment in an adult MFS patient with OSA using an oral appliance (OA). The patient was a 48-year-old Japanese woman of MFS, diagnosed with moderate OSA (apnea hypopnea index [AHI] = 27.0; lowest oxygen saturation [SaO2] = 78%; maximum apnea time = 114 s]). An OA was selected as the treatment option, and post-treatment sleep study indicated a reduction in AHI to 8.8/h with an improvement in other factors (lowest SaO2 = 84%; maximum apnea time = 66 s). Additionally, the treatment resulted in a reduction in BNP levels (81.3 from 110.2 pg/ml), and the patient’s cardiac function was stable over the period in which the patient received OA treatment. This study provides a basis for the future appropriate understanding and management of OSA of MFS patients.
Keywords: OSA, oral appliance, Marfan’s syndrome
How to cite this article:
Akifumi Enomoto, Yuko Kinoshita, Atsushi-Doksa Lee, Miho Sukedai, Takeshi Shimoide. Efficacy of an oral appliance in an adult Marfan syndrome patient with obstructive sleep apnea. International Journal of Case Reports, 2021 5:231. DOI: 10.28933/ijcr-2021-07-0606
1. Sampol, G., et al., Obstructive sleep apnea and thoracic aorta dissection. Am J Respir Crit Care Med, 2003. 168(12): p. 1528-31. 10.1164/rccm.200304-566OC.
2. Kyzer, S. and I. Charuzi, Obstructive sleep apnea in the obese. World J Surg, 1998. 22(9): p. 998-1001.
3. Taddei, M., et al., Effects of rapid maxillary expansion and mandibular advancement on upper airways in Marfan’s syndrome children: a home sleep study and cephalometric evaluation. Sleep Breath, 2015. 19(4): p. 1213-20. 10.1007/s11325-015-1141-y.
4. Saruhara, H., et al., Obstructive sleep apnea as a potential risk factor for aortic disease. Heart Vessels, 2012. 27(2): p. 166-73. 10.1007/s00380-011-0135-3.
5. Cistulli, P.A., et al., Aortic root dilatation in Marfan’s syndrome: a contribution from obstructive sleep apnea? Chest, 1997. 111(6): p. 1763-6.
6. Kohler, M., et al., The prevalence of obstructive sleep apnoea and its association with aortic dilatation in Marfan’s syndrome. Thorax, 2009. 64(2): p. 162-6. 10.1136/thx.2008.102756.
7. Verbraecken, J., et al., Aortic root diameter and nasal intermittent positive airway pressure treatment in Marfan’s syndrome. Clin Genet, 2003. 63(2): p. 131-4.
8. Wood, J.R., et al., Pulmonary disease in patients with Marfan syndrome. Thorax, 1984. 39(10): p. 780-4.
9. von Kodolitsch, Y., et al., The role of the multidisciplinary health care team in the management of patients with Marfan syndrome. J Multidiscip Healthc, 2016. 9: p. 587-614. 10.2147/JMDH.S93680.
10. Doff, M.H., et al., Long-term oral appliance therapy in obstructive sleep apnea syndrome: a controlled study on temporomandibular side effects. Clin Oral Investig, 2012. 16(3): p. 689-97. 10.1007/s00784-011-0555-6.
This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.